Haemonetics Corp
NYSE:HAE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
71.16
97.37
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Haemonetics Corp
Gross Profit
Haemonetics Corp
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Haemonetics Corp
NYSE:HAE
|
Gross Profit
$735.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
||
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Gross Profit
$2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
||
ICU Medical Inc
NASDAQ:ICUI
|
Gross Profit
$769.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
||
Align Technology Inc
NASDAQ:ALGN
|
Gross Profit
$2.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
||
Lantheus Holdings Inc
NASDAQ:LNTH
|
Gross Profit
$969.6m
|
CAGR 3-Years
78%
|
CAGR 5-Years
41%
|
CAGR 10-Years
25%
|
||
Merit Medical Systems Inc
NASDAQ:MMSI
|
Gross Profit
$620.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
Haemonetics Corp
Glance View
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.
See Also
What is Haemonetics Corp's Gross Profit?
Gross Profit
735.3m
USD
Based on the financial report for Sep 28, 2024, Haemonetics Corp's Gross Profit amounts to 735.3m USD.
What is Haemonetics Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
5%
Over the last year, the Gross Profit growth was 13%. The average annual Gross Profit growth rates for Haemonetics Corp have been 19% over the past three years , 10% over the past five years , and 5% over the past ten years .